1. Market Research
  2. > Biotechnology Market Trends
  3. > Global Royalty Financing Deals in Pharma, Biotech and Diagnostics 2010-2015

The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2005-2015 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2005 to early 2015.

The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all partnering deals announced since 2005 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2005. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2005, including a summary of the recent literature on the subject.

Chapter 3 provides an average benchmark royalty rates. The chapter includes numerous tables and figures summarizing the benchmark royalty rates by stage of development, therapy area and technology area.

Chapter 4 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal. The chapter includes numerous case studies for actual deals where royalty rates have been disclosed.

Chapter 5 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates, and why.

Chapter 6 provides comprehensive and detailed access to deals which disclose a royalty rate since 2005 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.

In addition the report includes a comprehensive appendix listing of all deals where a royalty rate has been disclosed announced since 2005, numbering over 700 deals. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2005.

In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.


Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2005-2015 provides the reader with the following key benefits:

In-depth understanding of royalty rate partnering deal trends since 2005
Analysis of the structure of royalty clauses with numerous real life case studies
Comprehensive listing of all partnering deals since 2005 where a royalty rate is disclosed, together with deal terms, value and press release
Comprehensive access to actual partnering deal contracts entered into by the world’s life science companies where a royalty rate is disclosed
Insight into the royalty terms included in a licensing agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2005-2015 is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2005-2015 includes:

Trends in royalty rates in the biopharma industry since 2010
Analysis of royalty rate clause structure
Case studies of real-life licensing deals which disclose royalty rates
Comprehensive listing of licensing deals which disclose royalty rates since 2005
Access to licensing contract documents which disclose royalty rates
The leading licensing deals by royalty rate value since 2005
Most active royalty rate disclosures since 2005

In Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2005-2015 available deals and contracts are listed by:

Company A-Z
Headline value
Therapeutic area
Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

Table Of Contents

Global Royalty Financing Deals in Pharma, Biotech and Diagnostics 2010-2015
Executive Summary

Chapter 1 - Introduction
1.1. What are royalties?
1.2. History of royalty rates
1.3. Royalties in pharma and biotech
1.4. Royalties versus revenue share
1.5. Overview of the report

Chapter 2 - An overview of pharma and biotech royalty rates
2.1. Trends in royalty rates 2005-2015
2.2. Royalty rate disclosure in pharma and biotech
2.3. How do revenue shares figure?
2.4. A review of recent literature
2.5. Royalty rates in the future

Chapter 3 - Average royalty rates for pharma and biotech partnering
3.1. Royalty rates in early stage deals
3.2. Royalty rates by stage of development
3.3. Royalty rates by therapy area

Chapter 4 - The royalty clause in pharma and biotech deals
4.1. Partnering agreement structure
4.2. Structure of a typical royalty clause
4.3. Example royalty clauses
4.3.1. Case study 1: Merck Serono-Opexa Therapeutics
4.3.2. Case study 2: Aradigm - Grifols
4.3.3. Case study 3: Forect Laboratories - Trevena
4.3.4. Case study 4: Sage Therapeutics - University of California

Chapter 5 - Companies actively disclosing royalty rates
5.1. Most active companies in disclosing royalty rates
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Office of the Chief Scientist
Ligand Pharmaceuticals
Pfizer
Genentech
Ipsen
Genzyme
Indevus Pharmaceuticals
5.2. Top partnering deals by royalty rate
5.3. The role of bigpharma and bigbiotech in royalty rate disclosure
5.2. Top partnering deals by royalty rate

Chapter 6 - Royalty rate contract directory
Explore royalty rates within the deal contract document to gain greater insight
6.1. Company A-Z
6.2. By stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
6.3. By therapeutic target
Anaesthetics
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Gynaecology
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Orphan disease
Pediatrics
Psychiatry
Public health
Respiratory
Sexual health
6.4. By technology type
Analysis
Animal models
Antibiotics
Antibodies
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Biosimilars/Bio-betters
Blood products
Cell culture
Clinical testing
Devices
Diagnostics
Discovery tools
Drug delivery
Enabling technology
Equipment
Gene therapy
Genomics
Implant
In vitro models
Microarray
Nanotechnology
Natural product
Oligonucleotide
Packaging
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Regenerative medicine
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Software tools
Transgenics
Vaccines

Appendices
Appendix 1 - Royalty rates in deals - by company A-Z
Appendix 2 - Royalty rates in deals - by therapy area
Appendix 3 - Royalty rates in deals - by stage of development at signing
Appendix 4 - Royalty rates in deals - by technology type
Appendix 5 - Royalty rate references
Appendix 6 - Resources
Appendix 7 - Deal type definitions
Appendix 8 - Example royalty rate deal contract document

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

Table of figures
Figure 1: Trends in pharma and biotech royalty rates, 2005-2015
Figure 2: Frequency of royalty rate disclosure 2005-2015
Figure 3: Royalty rates in early stage at deal signing - 2005-2015
Figure 4: Royalty rates by phase of development at deal signing - 2005-2015
Figure 5: Royalty rates by therapy area - 2005-2015
Figure 6: Components of the partnering deal structure
Figure 7: Components of the partnering royalty clause
Figure 8: Most active companies disclosing royalty rate 2005-2015
Figure 9: Top deals by royalty rate 2005-2015
Figure 10: Bigpharma - top 50 - deals with royalty disclosure 2005 to 2015
Figure 11: Bigpharma deals with royalty rate disclosed - 2005 to 2015
Figure 12: Bigbiotech - top 50 - deals with royalty disclosure 2005 to 2015
Figure 13: Bigbiotech deals with royalty rate disclosed - 2005 to 2015
Figure 14: Deals disclosing revenue share 2005-2015
Figure 15: Royalty rates - anaesthetics deals - 2005-2015
Figure 16: Royalty rates - cardiovascular deals - 2005-2015
Figure 17: Royalty rates - central nervous system deals - 2005-2015
Figure 18: Royalty rates - dental deals - 2005-2015
Figure 19: Royalty rates - dermatology deals - 2005-2015
Figure 20: Royalty rates - gastrointestinal deals - 2005-2015
Figure 21: Royalty rates - genetic disorder deals - 2005-2015
Figure 22: Royalty rates - genitourinary deals - 2005-2015
Figure 23: Royalty rates - gynaecology deals - 2005-2015
Figure 24: Royalty rates - hematology deals - 2005-2015
Figure 25: Royalty rates - hospital care deals - 2005-2015
Figure 26: Royalty rates - immunology deals - 2005-2015
Figure 27: Royalty rates - infectives deals - 2005-2015
Figure 28: Royalty rates - metabolic deals - 2005-2015
Figure 29: Royalty rates - musculoskeletal deals - 2005-2015
Figure 30: Royalty rates - obstetrics deals - 2005-2015
Figure 31: Royalty rates - oncology deals - 2005-2015
Figure 32: Royalty rates - ophthalmics deals - 2005-2015
Figure 33: Royalty rates - orphan disease deals - 2005-2015
Figure 34: Royalty rates - pediatrics deals - 2005-2015
Figure 35: Royalty rates - psychiatry deals - 2005-2015
Figure 36: Royalty rates - public health deals - 2005-2015
Figure 37: Royalty rates - respiratory deals - 2005-2015
Figure 38: Royalty rates - sexual health deals - 2005-2015
Figure 39: Royalty rates - discovery phase of development at deal signing - 2005-2015
Figure 40: Royalty rates - preclinical phase of development at deal signing - 2005-2015
Figure 41: Royalty rates - phase I phase of development at deal signing - 2005-2015
Figure 42: Royalty rates - phase II phase of development at deal signing - 2005-2015
Figure 43: Royalty rates - phase III phase of development at deal signing - 2005-2015
Figure 44: Royalty rates - registration phase of development at deal signing - 2005-2015
Figure 45: Royalty rates - marketed phase of development at deal signing - 2005-2015
Figure 46: Royalty rates - formulation phase of development at deal signing - 2005-2015
Figure 47: Online partnering resources
Figure 48: Deal type definitions
Figure 49: Licensing agreement for rhAAT - rEVO Biologics, LFB Biotechnologies - March 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

  • $ 18000
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global bioreactors market is expected to reach to USD 1,417 million by 2021 from USD 955 million in 2015, at a CAGR of 6.8% between 2015 and 2021.The increase in adoption of single-use technologies, ...

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

  • $ 12800
  • Industry report
  • September 2016
  • by Venture Planning Group

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800. VPGMarketResearch’s new report is a study of the major business opportunities emerging in the European cance ...

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

  • $ 8470
  • Industry report
  • November 2016
  • by La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing - R&D Drug Pipeline Database: 1-Year Subscription - Flat-Rate Subscription to La Merie Publishing Reports & News Services A one-yea ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.